Introduction

Overview of receptor activator of nuclear factor kβ (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) signaling system
The molecular triad involving RANK/RANKL/OPG cytokine system has been observed to influence various physiological and pathological processes throughout the body. These include bone modeling and remodeling, mammary gland development, tumor cell development and migration, and modulation of adaptive immunity ( Figure 1 ). [1] [2] [3] [4] The role of this signaling system has been well emphasized in bone where RANKL/ RANK signaling mediates osteoclastogenesis and bone resorption via paracrine signaling between osteoblast (RANKL) and osteoclast (RANK) cells. OPG produced by osteoblast and stromal cells acts as a soluble decoy receptor for RANKL and hence prevents osteoclast differentiation and activation by interfering with RANKL-RANK interaction. 1 RANK is also constitutively expressed in mammary epithelial tissues where RANKL works through RANK to provide proliferative and survival signals and thereby promotes the final stages of lactating mammary gland development. 5 It has also been shown to be involved in thermoregulation signaling in females (linked with submit your manuscript | www.dovepress.com
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Sisay et al ovarian sex hormones) possibly via the COX 2 -PGE 2 /EP 3 R pathway, vascular calcification, and atherosclerosis by cross talking with the renin-angiotensin system. [6] [7] [8] [9] [10] 
Methods
In this review, both open access scholarly sources and subscription based journals were utilized for the study. Legitimate databases and indexing services including directory of open access journals, PubMed, PubMed Central, Medline, Scopus, and ProQuest were considered for the collection of articles related to the topic of interest. Other supplementary sources such as Google Scholar, WorldCat, and ResearchGate were also used for extensively collecting updated and sufficient information on this topic. For subscription based journals, however, Hinari: World Health Organization for developing countries was used to access such journals (eg, Elsevier journals, subscribed journals in PubMed, Science Direct, etc.). The primary key terms used during data collection were "RANK," "RANKL," "OPG," "RANK/RANKL/OPG system," "cancer," "tumor," and "therapeutic." In each of the databases and web directories, Boolean logic (AND, OR) was routinely applied to connect the key terms. What is more, truncation and alternative terms were also employed to expand the chance of obtaining related articles to the topics of interest. Based on these key terms and following in-depth screening of the relevance of each and every article for the topic, only articles that are highly relevant to this review were included and duplicated articles were excluded from the study in advance. Excluding the background, 73 references were filtered for the body of this review. Coming to the timing distribution of references cited, the majority of references, 52 (71.23%), were published from 2010 to 2017. Data collection was conducted from September 2016 to April 2017.
Overview of RANK/RANKL/OPG system and cancer
Primary tumors will commonly metastasize into bone. Tumors such as breast and prostate cancers typically have a greater chance of inducing secondary cancers within bone.
11
Based on Stephen Paget's seed and soil theory, the bone microenvironment provides a conducive area (fertile soil) in which the seeds (secondary tumors) can easily grow in. RANK and RANKL have been known to be involved in cancer cell migration and development in bone. 12 Secondary tumors within the bone will secrete several growth factors and cytokines which stimulate osteoblast cells. Upon stimulation, osteoblast cells increase the expression and release of RANKL which in turn acts either on the RANK receptor found on the osteoclast cells or soluble decoy receptor (OPG) that circulates in body fluids. RANKL-RANK interaction activates osteoclasts to further release growth factors such as tumor growth factor β and insulin-like growth factor 1 from the bone matrix which in turn stimulate parathyroid Figure 1 The role of RANK/RANKL signaling system in various physiological and pathophysiological processes. Abbreviations: RANK, receptor activator of nuclear factor kβ; RANKL, RANK ligand.
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RANK/RANKL/OPG system in tumorigenesis and metastasis hormone-related peptide production and promote tumor growth. This interaction between tumor cells and the bone microenvironment results in a vicious cycle of bone destruction and tumor growth. Generally, skeletal-related events (SREs) are used to describe a collection of adverse events associated with bone metastases. SREs include pathologic fractures that require surgery or chemotherapy, spinal cord compression, and less frequently malignant hypercalcemia. 11, 13, 14 RANKL was also observed to be more accurate than conventional markers in the breast cancer subgroup, and was a better predictor of bone progression than N-terminal telopeptides of type I collagen. The study suggested that RANKL could serve as an accurate marker of bone response in metastatic patients. High RANKL levels may identify patients with a shift in bone homeostasis toward bone resorption.
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The role of RANK/RANKL/OPG system in solid cancers Primary bone tumors Malignant tumors of the bone can be either primary tumors or secondary (metastasized) tumors. Primary tumors include osteosarcoma, multiple myeloma, and giant cell tumor of the bone (Table 1) . Osteosarcoma is the most common primary malignant tumor of the bone. 16 This triad system also plays a significant role in various solid malignancies that are capable of metastasizing to bone. These include breast cancer, prostate cancer, and lung cancer, among others. 22 This triad system is by far strongly implicated in the physiology of mammary gland development and pathogenesis of breast cancer cells. 5, 23, 24 The role of the RANK/RANKL/OPG triad system goes beyond involvement of breast cancer pathogenesis. The second most common target is prostate cancer. It has also been implicated in the pathogenesis of several and rare malignant tumors such as lung cancer, renal cell carcinoma, hepatocellular carcinoma, and melanoma (Table 2) . 22, 25 The regulatory function of RANKL is one of the key factors in progesterone-induced proliferation of the breast. Progesterone has a direct action on progesterone receptor (PR) expressing cells but PR-negative cells are affected indirectly through RANKL-induced paracrine actions leading to the proliferation of mammary epithelial PR-negative cells. RANK induces epithelial to mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. 26 RANKL stimulation of RANK expressing cells increased multidrug resistance protein 1, breast cancer resistance protein, and lung resistance protein 1 expression and decreased Bim expression through various signaling molecules. These results indicate that the RANK/ RANKL system induces chemoresistance through the activation of multiple signal transduction pathways. 27 What is more, expression of RANKL was observed during pregnancy. This evidence suggests that RANKL can be used as a potential breast cancer therapeutic target particularly in young women and pregnancy-associated tumors. RANKL/RANK has also been shown to control breast cancer 1 gene mutation-driven mammary tumors. Besides, the E3 ubiquitin ligase Cbl-b protein has been shown to improve the prognosis of RANK + breast cancer patients via inhibiting RANKL-induced cancer cell migration and metastasis ( Figure 2 ).
28-31
Other solid cancers RANKL, RANK, and OPG were variably expressed in tumors of the thyroid, including papillary carcinomas, medullary carcinomas, and macrovascular adenomas. 60 Increased Table 1 The role of RANKL/RANK/OPG system in primary malignant tumors of the bone
Primary bone tumors RANKL/RANK/OPG system and its role in tumorigenesis References
Osteosarcoma -↑ RANKL/OPG ratio was observed in the serum of patients with osteosarcoma -in experimental animals, OPG treatment achieved not only the prevention of osteosarcoma-induced osteolysis but also the inhibition of associated tumor development that improved the survival rate in treatment groups -RANKL blockade has been shown to prevent and treat aggressive osteosarcomas Grimaud et al 17 Lamoureux et al 18 Chen et al 19 Multiple myeloma Deregulation of the triad system (expression of more RANKL and/or more lysosomal degradation of OPG) enhances osteoclastogenesis 
3806
Sisay et al serum OPG has also been correlated with poor prognosis in gastric carcinoma 61 and bladder carcinoma. 62 RANK overexpression was also considered as a novel esophageal cancer marker. 63 
Nonsolid cancers
Beyond its role in the pathogenesis of several primary and secondary solid malignant tumors, this signaling system has been known to be involved in certain nonsolid cancers such as chronic lymphocytic leukemia and acute myeloid leukemia (AML).
Leukemia
Expression of RANKL was also observed in chronic lymphocytic leukemia and has been known to induce inflammatory cytokines involved in the disease pathogenesis (tumor necrosis factor [TNF], interleukin [IL]-6, and IL-8). A novel Fc-engineered RANK fusion protein was shown to induce natural killer (NK) cell-mediated antitumor immunity against RANKL expressing targets. 12 Besides, RANKL influences the interaction of NK and AML cells by mediating a feedback loop that involves the release of factors by the latter which upregulates RANK on the former. In addition to the immediate inhibitory effects of RANKL-induced factors, RANK is readily available to interact with RANKL expressed by AML cells. This process leads to the activation of a bidirectional signal transduction cascade that causes the delivery of RANK-mediated inhibitory signals to NK cells and perpetuates RANKL reverse signaling process in AML cells. 64 The adhesion of the freshly isolated lymphoma B cells to bone marrow stromal cells or freshly isolated lymphoma stromal cells inhibited B cell spontaneous apoptosis in culture. This inhibition of apoptosis correlated with decreased cleavage of caspase-3/8 and increased activation of canonical and noncanonical nuclear factor kappa B signaling pathway. 65 Prognostic analysis revealed a higher probability of overall survival in cases with lower RANKL expression (,1.6 and $1.6, 15.6 vs 12.2 months, P=0.008, hazard ratio 0.36, P=0.008). The study revealed that RANKL is a promising marker to forecast patients' prognosis in AML. 66 
Potential therapeutic approaches
Considering this molecular triad system as a hot spot in the area of oncology research, several therapeutic agents have been developed over the last decade. These include humanized monoclonal antibodies, herbal medicines, RNA interference technology, and proteolytic enzymes, among others (Table 3 ). Notes: ↑, increased, unregulated; ↓, decreased, downregulated, attenuated. Abbreviations: BMM, bone marrow macrophages; CReB, cAMP response element-binding protein; FDA, US Food and Drug Administration; GCTB, giant cell tumor of the bone; JNK, Jun N-terminal kinase; NF-κB, nuclear factor kappa B; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor kβ; RANKL, RANK ligand; weAT, water extract of Acer tegmentosum; 3D, three-dimensional; TRAiL, tumor necrosis factor-related apoptosis inducing ligand; NeeDK, aspargine, glutamic acid, glutamic acid, aspartic acid and lysine; TRAF, tumor necrosis factor receptor associated factor.
Conclusion
The role of the RANK/RANKL/OPG system is well emphasized in this review article. Beyond regulation of many biological functions throughout the body, the system has a key role in the pathophysiology of various disorders. This triad system can be considered as a hot spot in the area of experimental oncology. This review revealed that the system is strongly implicated in the development of mammary gland structures and tumorigenesis of lobuloalveolar cells of the breast. It has also been shown to take part in the pathogenesis of several solid and nonsolid cancer types including prostate cancer, lung cancer, renal cell carcinoma, melanoma, and leukemia. What is more, the system is highly associated with tumor invasiveness and metastasis. Considering the role of this triad system in cancer cell development and metastasis, scientists are striving to discover therapeutic agents targeting these TNF-related proteins (RANK, RANKL, and OPG) and their downstream signaling pathways for better treatment of cancer and osteoporosis (bone osteolysis) in the near future. Some of these agents include denosumab, enteropeptidase enzymes, small hairpin RNAs, and Jolkinolide B.
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